Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Prepaid Assets (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Prepaid Assets readings, the most recent being $9.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets changed 0.07% year-over-year to $9.5 million, compared with a TTM value of $9.5 million through Dec 2025, changed 0.07%, and an annual FY2025 reading of $9.5 million, changed 0.07% over the prior year.
  • Prepaid Assets hit $9.5 million in Q4 2025 for Apellis Pharmaceuticals, down from $31.6 million in the prior quarter.
  • The five-year high for Prepaid Assets was $70.7 million in Q4 2021, with the low at $8.6 million in Q4 2023.
  • Median Prepaid Assets over the past 5 years was $19.9 million (2021), compared with a mean of $22.7 million.
  • The sharpest move saw Prepaid Assets skyrocketed 932.06% in 2021, then tumbled 76.36% in 2023.
  • Year by year, Prepaid Assets stood at $70.7 million in 2021, then plummeted by 48.57% to $36.4 million in 2022, then plummeted by 76.36% to $8.6 million in 2023, then rose by 10.65% to $9.5 million in 2024, then grew by 0.07% to $9.5 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $9.5 million, $31.6 million, and $29.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.